HCPCS J0132: Injection, Acetylcysteine 100 mg

HCPCS Level II code J0132 represents a 100 mg injectable dose of acetylcysteine, used clinically as a mucolytic and as an antidote in certain toxic ingestions. Nationally, this code matters for hospital outpatient departments, emergency departments, and infusion centers because it captures billing for a commonly administered parenteral medication with specific dosing units. Appropriate coding affects drug utilization tracking, cost reporting, and payer reimbursement for infusion services.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, common billing practices, and typical sites of service. The publication provides benchmarks where available, clarifies clinical use cases tied to injectable acetylcysteine, and summarizes relevant policy considerations that influence coverage and billing for injectable medications at the national level.

This summary is intended to orient clinicians, billing professionals, and policy analysts to the primary purpose of J0132, the settings in which it is billed, and the payer landscape relevant to national reimbursement and utilization discussions. Data not available in the input will be flagged within the full publication.

Billing Code Overview

HCPCS Level II code J0132 denotes Injection, acetylcysteine, 100 mg. This code represents a single-unit injectable formulation of acetylcysteine, an agent commonly used as a mucolytic and as an antidote in certain toxic ingestions. The service type associated with this code is injectable medication administration. The typical site of service for procedures billed with J0132 is outpatient infusion or clinic settings, including emergency departments and infusion centers where parenteral medications are administered.

Data not available in the input.

Clinical Context

A typical patient is an adult presenting to an emergency department or infusion center with documented or suspected acetaminophen (paracetamol) overdose. The patient has either a known ingestion time within 24 hours or presents with elevated transaminases and a toxicology evaluation indicating significant risk of hepatic injury. After triage and initial assessment (vital signs, airway/breathing/circulation stabilization), serum acetaminophen level is obtained and plotted on the Rumack–Matthew nomogram when applicable. If the measured level is above the treatment threshold or if ingestion timing is uncertain with clinical concern for hepatotoxicity, intravenous N-acetylcysteine is ordered. Pharmacy prepares J0132 (Injection, acetylcysteine, 100 mg) in appropriate concentration and volume. Nursing administers the infusion per hospital protocol (loading dose followed by maintenance infusions) with continuous monitoring for anaphylactoid reactions, vital sign changes, and response to therapy. Laboratory monitoring (liver function tests, INR, electrolytes) is performed serially during and after therapy. Discharge or admission decisions are based on clinical course, lab trends, and completion of the NAC protocol.

Coding Specifications

Modifier	Description	When to Use
`11`	Provider specialty designation	Use when billing reflects the provider's usual specialty for services (institutional reporting of physician specialty when required).

Taxonomy Code	Specialty	Notes
`208000000X`	Emergency Medicine	ED physicians commonly order and oversee NAC therapy for overdose.
`208000000N`	Medical Toxicology	Toxicologists provide guidance on NAC protocols and complex overdose management.
`207RH0000X`	Internal Medicine	Hospitalists oversee inpatient NAC administration and monitoring.
`363LF0000X`	Pharmacy	Clinical pharmacists prepare and verify NAC intravenous formulations and dosing.
`364S00000X`	Nursing	Infusion and emergency nurses administer NAC and monitor for reactions.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`T39.1X1A`	Poisoning by 4-aminophenol derivatives, accidental (unintentional), initial encounter	Represents unintentional acetaminophen overdose requiring NAC therapy.
`T39.1X2A`	Poisoning by 4-aminophenol derivatives, intentional self-harm, initial encounter	Represents intentional acetaminophen overdose where NAC is indicated.
`T39.1X3A`	Poisoning by 4-aminophenol derivatives, assault, initial encounter	Assault-related acetaminophen poisoning scenarios where NAC may be required.
`T39.1X4A`	Poisoning by 4-aminophenol derivatives, undetermined, initial encounter	Used when intent is unclear; NAC indicated based on toxicity assessment.
`R94.5`	Abnormal results of liver function studies	Elevated LFTs prompt initiation or continuation of NAC and monitoring for hepatotoxicity.
`K71.6`	Toxic liver disease with hepatitis	Indicates hepatic injury from toxins such as acetaminophen; NAC is part of management for acetaminophen-induced injury.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Often used for billing infusion time for the initial NAC loading infusion when billed separately.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)	Used for subsequent hourly infusion time for maintenance NAC dosing when time-based infusion billing is appropriate.
`36415`	Collection of venous blood by venipuncture	Performed for baseline and serial labs (acetaminophen level, LFTs, INR, electrolytes) during NAC therapy.
`84460`	Assay of acetaminophen; quantitative	Directly related diagnostic test that informs the decision to initiate and continue NAC therapy.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if NAC is administered intramuscularly in a specific protocol (intravenous administration is typical for `J0132`).

OpenPayer

Summary & Overview